Genomic Profiling of T-Cell Neoplasms Reveals Frequent <i>JAK1</i> and <i>JAK3</i> Mutations With Clonal Evasion From Targeted Therapies

Abstract

These results underscore the utility of profiling occurrences of resistance to standard regimens and support JAK enzymes as rational therapeutic targets for T-cell leukemias and lymphomas.